COMMUNIQUÉS West-GlobeNewswire

NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
27/03/2024
CARMEL, Ind., March 27, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
27/03/2024
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – AXIM Biotechnologies [...]
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
27/03/2024
PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain [...]
NEXGEL Reschedules Fourth Quarter and Full Year 2023 Financial Results Conference Call to Monday, April 1st at 8:30 a.m. ET Due to Holiday
27/03/2024
LANGHORNE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
27/03/2024
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Årsregnskab 2023 – Et begivenhedsrigt år for selskabet
27/03/2024
2023 var et begivenhedsrigt år for selskabet, hvor den primære fokus i første halvår bestod i at overlevere driften af den tidligere aktivitet til Zevra samt at forlige den anlagte retssag i USA. I maj 2023 blev en ny [...]
SFWJ/MedCana Announces Significant Progress Across Its Operations, Eyes Global Expansion and Enhanced Profitability
27/03/2024
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- via IBN -- SFWJ, doing business as MedCana, a leading entity in the cannabis and agricultural technology sectors, today announces remarkable advancements across its [...]
UPDATE – Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223
27/03/2024
-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223 therapy in prostate [...]
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
27/03/2024
The stenoparib Phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development Further development of IXEMPRA ® and dovitinib [...]
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
27/03/2024
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical [...]
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
27/03/2024
ROSCREA, Ireland and FREIBURG, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high [...]
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
27/03/2024
ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s [...]
Dyadic to Attend Industry Events in April
27/03/2024
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
27/03/2024
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
27/03/2024
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES
27/03/2024
LB-100 IS SYNERGISTIC WITH WEE1 INHIBITION IN KILLING CANCER CELLS; FINDING OPENS NEW TREATMENT STRATEGY IN ADDITION TO THREE CURRENT LIXTE CLINICAL TRIALS PASADENA, CA, March 27, 2024 (GLOBE NEWSWIRE) -- LIXTE [...]
CorMedix Inc. to Present at the Needham Annual Healthcare Conference
27/03/2024
BERKELEY HEIGHTS, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of [...]
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
27/03/2024
SEATTLE, March 27, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]
Markham Fertility Centre and humm Canada partner to make fertility treatments more accessible
27/03/2024
MARKHAM, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- Markham Fertility Centre (MFC) and humm Canada proudly come together to announce better financing options for patients seeking fertility treatments. Time, cost, and [...]

Pages